DK3395817T3 - Pyrido[1,2-a]pyrimidonanalog, krystalform deraf, mellemprodukt deraf og fremgangsmåde til fremstilling deraf - Google Patents

Pyrido[1,2-a]pyrimidonanalog, krystalform deraf, mellemprodukt deraf og fremgangsmåde til fremstilling deraf Download PDF

Info

Publication number
DK3395817T3
DK3395817T3 DK16874904.2T DK16874904T DK3395817T3 DK 3395817 T3 DK3395817 T3 DK 3395817T3 DK 16874904 T DK16874904 T DK 16874904T DK 3395817 T3 DK3395817 T3 DK 3395817T3
Authority
DK
Denmark
Prior art keywords
pyrido
manufacture
crystal shape
pyrimidone
analog
Prior art date
Application number
DK16874904.2T
Other languages
English (en)
Inventor
Tao Yu
Ning Li
Lingwei Kong
Peipei Jiang
Yong Wang
Zhemin Rong
Changjun Wang
Feng Guo
Zongbin Li
Zheng Wang
Jiahu Wu
Chengde Wu
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Application granted granted Critical
Publication of DK3395817T3 publication Critical patent/DK3395817T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK16874904.2T 2015-12-16 2016-12-16 Pyrido[1,2-a]pyrimidonanalog, krystalform deraf, mellemprodukt deraf og fremgangsmåde til fremstilling deraf DK3395817T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510951482 2015-12-16
PCT/CN2016/110284 WO2017101847A1 (zh) 2015-12-16 2016-12-16 吡啶并[1,2-a]嘧啶酮类似物、其晶型、其中间体及其制备方法

Publications (1)

Publication Number Publication Date
DK3395817T3 true DK3395817T3 (da) 2022-03-21

Family

ID=59055711

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16874904.2T DK3395817T3 (da) 2015-12-16 2016-12-16 Pyrido[1,2-a]pyrimidonanalog, krystalform deraf, mellemprodukt deraf og fremgangsmåde til fremstilling deraf

Country Status (14)

Country Link
US (1) US10479789B2 (da)
EP (1) EP3395817B1 (da)
JP (1) JP7037483B2 (da)
KR (1) KR20180095565A (da)
CN (1) CN108602815B (da)
AU (1) AU2016369835B2 (da)
CA (1) CA3008689A1 (da)
DK (1) DK3395817T3 (da)
ES (1) ES2908498T3 (da)
HK (1) HK1256044A1 (da)
PL (1) PL3395817T3 (da)
RU (1) RU2753696C2 (da)
WO (1) WO2017101847A1 (da)
ZA (1) ZA201804007B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220213060A1 (en) * 2019-05-13 2022-07-07 Luoxin Healthcare Science and Technology Development (Beijing) Ltd. Crystal Form of Quinazolinone Compound and Preparation Method Therefor
EP4119557A4 (en) * 2020-03-10 2024-04-10 Chia Tai Tianqing Pharmaceutical Group Co Ltd PHARMACEUTICAL COMBINATION WITH A PYRIDINO[1,2-A PYRIMIDINONE COMPOUND
EP4197539A1 (en) * 2020-09-15 2023-06-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of pyrido[1,2-a]pyrimidinone compound in treating peripheral t cell lymphoma
WO2022121929A1 (zh) * 2020-12-08 2022-06-16 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮化合物的治疗妇科肿瘤的用途
CN115671289B (zh) * 2021-07-27 2024-04-26 广州嘉越医药科技有限公司 药物组合及其应用
WO2023169488A1 (zh) * 2022-03-09 2023-09-14 正大天晴药业集团股份有限公司 包括吡啶并[1,2-a]嘧啶酮化合物和EGFR抑制剂的药物组合

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1699A (en) 2001-03-21 2006-12-26 Warner Lambert Co New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
EP2211615A4 (en) 2007-10-22 2010-10-13 Glaxosmithkline Llc PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
CN102206222B (zh) 2011-04-14 2013-04-10 中山大学 一种双脂肪氨基取代吲哚喹啉衍生物及其制备方法和制备抗肿瘤药物中的应用
CN103539777B (zh) 2012-07-13 2016-03-02 广东东阳光药业有限公司 Pi3激酶调节剂及其使用方法和用途
WO2014022128A1 (en) 2012-07-29 2014-02-06 Calitor Sciences, Llc Pi3 kinase modulators and methods of use
CN103788071A (zh) 2012-11-01 2014-05-14 中国人民解放军第二军医大学 N-(5-(喹啉-6-基)吡啶-3-基)苯磺酰胺衍生物、制备方法及治疗用途
US9868737B2 (en) 2014-06-17 2018-01-16 Cisen Pharmaceutical Co., Ltd. Pyridino[1,2-A]pyrimidone analogue used as MTOR/P13K inhibitor
CN105461711B (zh) * 2014-06-17 2018-11-06 正大天晴药业集团股份有限公司 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
US9856256B2 (en) 2014-06-17 2018-01-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyridino[1,2-A]pyrimidone analogue used as P13K inhibitor

Also Published As

Publication number Publication date
ZA201804007B (en) 2019-05-29
RU2018125475A3 (da) 2020-02-28
EP3395817A1 (en) 2018-10-31
US10479789B2 (en) 2019-11-19
CN108602815A (zh) 2018-09-28
CA3008689A1 (en) 2017-06-22
AU2016369835B2 (en) 2020-10-15
RU2018125475A (ru) 2020-01-16
EP3395817B1 (en) 2022-02-23
AU2016369835A1 (en) 2018-07-19
WO2017101847A1 (zh) 2017-06-22
HK1256044A1 (zh) 2019-09-13
JP7037483B2 (ja) 2022-03-16
KR20180095565A (ko) 2018-08-27
ES2908498T3 (es) 2022-04-29
EP3395817A4 (en) 2019-08-07
RU2753696C2 (ru) 2021-08-19
PL3395817T3 (pl) 2022-05-02
US20180319799A1 (en) 2018-11-08
CN108602815B (zh) 2020-07-28
JP2018537497A (ja) 2018-12-20

Similar Documents

Publication Publication Date Title
ZA201802976B (en) N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
DK3395817T3 (da) Pyrido[1,2-a]pyrimidonanalog, krystalform deraf, mellemprodukt deraf og fremgangsmåde til fremstilling deraf
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
EP3214437A4 (en) Sample supporting body and method of manufacturing sample supporting body
HK1254057A1 (zh) 用於製備膽汁酸衍生物的方法和中間體
LT3447137T (lt) Skystas fermento preparatas ir jo gamybos būdas
EP3421503A4 (en) SUGAMMADEX MANUFACTURE AND CLEANING PROCEDURE
DK3305785T3 (da) Pyrido[3,4-d]pyrimidinderivat og farmaceutisk acceptabelt salt deraf
HK1208144A1 (en) Artificial biological heart valve and the production methods thereof
EP3196328A4 (en) Enamel steel having high-temperature baking hardenability and manufacturing method therefor
EP3251635A4 (en) ADJUSTABLE HEIGHT SPINDLE AND METHOD FOR MANUFACTURING THE SAME
DK3348557T3 (da) Imidazo[1,2-a]pyridiner til behandling eller forebyggelse af hyperurekæmi eller gigt
HK1225723A1 (zh) 取代的咪唑並[1,2-a]吡啶甲酰胺及其用途
DK3315181T3 (da) Sammensat emne og fremgangsmåde til at fremstille samme
EP3395329A4 (en) PROCESS FOR THE PREPARATION OF LIPID BODIES AND THEIR USE
HK1246279A1 (zh) C14-位羥基酯化的雷公藤甲素氨基酸衍生物、及其製備方法和應用
IL266609A (en) Red blood cell targeted factor viii and method of using the same
EP3337845A4 (en) Non-isocyanate polyurethanes and process for the preparation and use thereof
EP3297573A4 (en) STENT AND METHOD OF USE
DK3481827T3 (da) Imidazo[1,2-a]pyridinderivater, fremgangsmåder til fremstilling og anvendelse deraf
GB201802644D0 (en) Monocyclic,thieno, pyrido and pyrrolo pyrimidine compounds and methods of use and manufacture of the same
EP3285797A4 (en) Gal-1 variants having immuno-modulating properties and methods of using the same
IL248033A0 (en) Sky compass and method for its calibration
EP3279182A4 (en) Acetylsalicylic acid derivative crystal and preparation method and use thereof
EP3615337A4 (en) SEQUENCING LOADS USING TEMPERATURE